Treatment Satisfaction With and Adherence to Disease-Modifying Antirheumatic Drugs in Adult Patients With Juvenile Idiopathic Arthritis
| Autor: | Anita Tollisen, Anne M Selvaag, Astrid Aasland, Joachim Sagen, Trude M Ingebrigtsen, Berit Flatø, Anners Lerdal |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Combination therapy Health Status Arthritis Disease Medication Adherence Treatment satisfaction 03 medical and health sciences Young Adult 0302 clinical medicine Rheumatology Quality of life Internal medicine Juvenile Medicine Humans Longitudinal Studies Prospective Studies 030203 arthritis & rheumatology business.industry medicine.disease Arthritis Juvenile Methotrexate Treatment Outcome Patient Satisfaction Antirheumatic Agents Quality of Life Drug Therapy Combination Female business Antirheumatic drugs Immunosuppressive Agents medicine.drug |
| Zdroj: | Arthritis careresearchReferences. 73(2) |
| ISSN: | 2151-4658 |
| Popis: | OBJECTIVE To examine medication satisfaction and adherence and their relationships to disease variables and health-related quality of life (HRQoL) in adults with juvenile idiopathic arthritis (JIA). METHODS Patients (n = 96, mean age 25 years, 67% female) completed questionnaires about their health status 19 years after disease onset. Patients receiving biologic disease-modifying antirheumatic drugs (bDMARDs) or methotrexate (MTX) were assessed with the 8-item Morisky Medication Adherence Scale (MMAS-8) and the Treatment Satisfaction Questionnaire for Medication (TSQM), including dimensions of effectiveness, side effects, convenience, and global satisfaction. RESULTS DMARDs were received by 52 patients (54%) (mean age 25 years, 75% female), of which 28 received MTX and 37 received bDMARDs. Patients receiving combination therapy of MTX and bDMARDs (n = 15) reported higher satisfaction with bDMARDs than MTX in the dimensions of side effects and global satisfaction (mean ± SD 92.9 ± 15.5 versus 56.2 ± 30.9, and mean ± SD 67.6 ± 19.8 versus 47.1 ± 21.7; P < 0.001 and P = 0.016, respectively). Patients receiving either bDMARDs (n = 22) or MTX (n = 13) reported higher satisfaction with bDMARDs than MTX for the dimensions of effectiveness and global satisfaction (mean ± SD 78.7 ± 15.4 versus 60.2 ± 19.9, and mean ± SD 73.6 ± 17.7 versus 52.3 ± 23.9; P = 0.004 and P = 0.005, respectively). Nearly one-half of patients (46%) reported low adherence (MMAS-8 score |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text